TRX-319 in Multiple Sclerosis, Primary Progressive: NCT07477639 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1/2
Clinical phase
Recruiting
Recruitment status
39
Planned enrollment
2028-08-01
Primary-completion proxy
Executive view
NCT07477639 evaluates TRX-319 in Multiple Sclerosis, Primary Progressive. The disclosed sponsor is Tr1x, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis., assessed over From baseline until 12 months post TRX319 Infusion.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07477639 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Multiple Sclerosis, Primary Progressive landscape. Drug & Asset MCP drug_fetch was queried for TRX-319, while Company & Deal Intelligence MCP organization_fetch was queried for Tr1x, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07477639 | TRX-319 | Phase 1/2 / Recruiting | Tr1x, Inc. | United States | To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive… From baseline until 12 months post TRX319 Infusion | 2028-08-01 |
| NCT07483450 | Ocrelizumab | Phase 4 / Active, not recruiting | Roche Holding AG | China | RMS Cohort: Annualized Protocol-defined Relapse Rate Up to approximately 1.6 years | 2027-12-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07477639 is a Phase 1/2, recruiting study with 39 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis.” over “From baseline until 12 months post TRX319 Infusion.” The retrieved endpoint description is: * Number of participants with severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) * Rate of Adverse Events of Special Interest (AESIs) in participants * The safety of TRX319 determined by negative Replication Competent Lentivirus (RCL) at approximately 3-months, 6-months, and 12-months.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 39 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Multiple Sclerosis, Primary Progressive. These records do not establish direct evidence for NCT07477639 unless the registration number matches.
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients…
Phase 3; n=236; Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration(Mean): Geometric Mean Ratio = 1.2851(90% CI, 1.2258 - 1.3473); Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration(Mean) = 3500 micrograms/milliliters*day (µg/mL*day) (Standard Deviation, 914) Source: https://clinicaltrials.gov/ct2/show/results/NCT05232825
A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Ace…
Phase 3; n=1016; ARR(Mean) = 0.182 Relapses per participant per year (Standard Error, 0.022); ARR(Mean) = 0.260 Relapses per participant per year (Standard Error, 0.029) Source: https://clinicaltrials.gov/ct2/show/results/NCT04121221
Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study
Phase 4; n=219; NEDA-3(Y3) = 78.6 % Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42548205/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
TRX-319 is indexed as CAR-Treg with CD19 biology and a global stage of Phase 1/2. The asset profile lists Tr1x, Inc. as an originator or developer.
Tr1x, Inc. is indexed in United States with the website http://www.tr1x.bio. Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases. The record lists 3 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether TRX-319 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07477639
Protocol source: https://clinicaltrials.gov/study/NCT07477639
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
TRX-319 in Multiple Sclerosis, Primary Progressive is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis. and 2028-08-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
